Hennion & Walsh Asset Management, Inc.

Position in VRDN — Viridian Therapeutics, Inc.\DE

CIK 1861642 Parsippany, NJ

Position in VRDN

as of Jun 30, 2026 · filed Jul 8, 2026 Compact

Position Value

$3,841,020

+$420,094 QoQ

Shares Held

209,092

+19.6% QoQ

Ownership

0.203%

of shares outstanding

% of Portfolio

0.15%

of 13F equity value

Holder Rank

of 12 holders

Holding Since

Jun 2023

13 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Hennion & Walsh Asset Management, Inc. holds $200,308,891 across 60 Biotechnology names. VRDN ranks #21 (1.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	JAZZ	Jazz Pharmaceuticals plc	48,019	$11,571,138
2	CELC	Celcuity Inc.	100,368	$10,500,500
3	URGN	UroGen Pharma Ltd.	276,696	$10,182,412
4	TVTX	Travere Therapeutics, Inc.	171,470	$9,741,210
5	SNDX	Syndax Pharmaceuticals Inc	342,883	$7,495,422
6	QURE	uniQure N.V.	142,113	$6,545,724
7	KURA	Kura Oncology, Inc.	568,845	$6,240,229
8	ARDX	Ardelyx, Inc.	1,211,690	$6,179,619

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,841,020	209,092	+19.6%	Shares	Sole	2026-07-08
2026-03-31	$3,420,926	174,894	+3.4%	Shares	Sole	2026-05-13
2025-12-31	$5,264,477	169,167	+9.6%	Shares	Sole	2026-01-14
2025-09-30	$3,330,614	154,338	-8.3%	Shares	Sole	2025-10-22
2025-06-30	$2,353,169	168,324	-15.5%	Shares	Sole	2025-08-07
2025-03-31	$2,685,121	199,193	-5.6%	Shares	Sole	2025-04-10
2024-12-31	$4,042,933	210,899	+6.8%	Shares	Sole	2025-01-15
2024-09-30	$4,490,872	197,401	+10.4%	Shares	Sole	2024-10-22
2024-06-30	$2,326,903	178,855	+62.9%	Shares	Sole	2024-07-19
2024-03-31	$1,922,948	109,820	+44.9%	Shares	Sole	2024-04-17
2023-12-31	$1,650,488	75,780	+179.5%	Shares	Sole	2024-01-10
2023-09-30	$415,898	27,112	+89.5%	Shares	Sole	2023-10-27
2023-06-30	$340,315	14,305	—	Shares	Sole	2023-08-09
No filing history on record for this holder in this stock.